- NeuPath Health (TSXV:NPTH), an owner and operator of chronic pain treatment clinics, has administered the first injection of Arthrosamid in North America at its Mississauga, Ontario location
- Arthrosamid is a hydrogel developed by Contura International, a biotechnology company based in Denmark, that offers up to four years of pain relief from knee osteoarthritis
- NeuPath operates a network of clinics in Ontario and Alberta specializing in comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions
- NeuPath Health stock is down by 5 per cent year-over-year and by over 70 per cent since inception in 2020
NeuPath Health (TSXV:NPTH), an owner and operator of chronic pain treatment clinics, has administered the first injection of Arthrosamid in North America at its Mississauga, Ontario location.
Arthrosamid is a hydrogel developed by Contura International, a biotechnology company based in Denmark, that offers up to four years of pain relief from knee osteoarthritis, a leading cause of disability among older adults. The hydrogel “integrates into the synovial tissue of the knee, helping to cushion the joint and reduce pain with a single dose,” according to Thursday’s news release, far outperforming painkillers and corticosteroid injections.
The addition opens NeuPath up to a market of four million Canadians who suffer from osteoarthritis, representing a C$6.4 billion economic burden, strengthening its leadership position in chronic pain treatments.
NeuPath has delivered operational improvements since inception in 2020, growing revenue every year amid diminishing net losses, including positive net income in two out of the past five quarters.
Leadership insights
“This is a major step forward in osteoarthritis options for Canadians,” Joe Walewicz, NeuPath’s chief executive officer, said in a statement. “It underscores our commitment to provide the best chronic pain care to our patients as we scale up our clinic network and expand our services across Canada. We continue to seek out proven, innovative treatments that leverage our growing market presence and the skills of our healthcare professionals.”
About NeuPath Health
NeuPath operates a network of clinics in Ontario and Alberta specializing in comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. The company also provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies.
NeuPath Health stock (TSXV:NPTH) is unchanged trading at C$0.19 per share as of 11:52 am ET. The stock is down by 5 per cent year-over-year and by over 70 per cent since inception in 2020.
Join the discussion: Find out what everybody’s saying about this healthcare stock on the NeuPath Health Inc. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image, generated by AI: Adobe Stock)
